Erratum to: Activation of nuclear factor κB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer: SHARPIN/NFκB in Prostate Cancer (Cancer, (2014), 120, 20, (3208-3218), 10.1002/cncr.28796);Activation of nuclear factor κb pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer

Cancer

Volumn 120, Issue 20, 2014, Pages 3208-3218

  Zhang, Yiming ^a,b   Huang, Hai ^a   Zhou, Huimin ^a   Du, Tao ^a   Zeng, Lexiang ^a   Cao, Yi ^a   Chen, Jieqing ^c   Lai, Yiming ^a   Li, Jin ^a   Wang, Ganping ^a   Guo, Zhenghui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SECOND PEOPLE S HOSPITAL OF SHENZHEN   (China)

Author keywords

Chemotherapy; Docetaxel; Livin; NFjB pathway; Prostate cancer; SHARPIN; Survivin

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5 (3 CARBOXYMETHOXYPHENYL) 2 (4,5 DIMENTHYLTHIAZOLY) 3 (4 SULFOPHENYL)TETRAZOLIUM; CARRIER PROTEINS AND BINDING PROTEINS; DOCETAXEL; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVIN; SHANK ASSOCIATED RH DOMAIN INTERACTING PROTEIN; SODIUM CHLORIDE; SURVIVIN; SYNAPTOTAGMIN I; TETRAZOLIUM; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; SHARPIN PROTEIN, HUMAN; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DOWNSTREAM PROCESSING; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SHARPIN GENE; SIGNAL TRANSDUCTION; UPREGULATION; CELL MOTION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM METASTASIS; NF-KAPPA B; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION; UBIQUITINS;

EID: 84908022001     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30497     Document Type: Erratum

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998;17:331-336.
3. Lim S, Sala C, Yoon J, et al. Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol Cell Neurosci. 2001;17:385-397.
4. Jung J, Kim JM, Park B, et al. Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 2010;340:161-167.
5. Wang Z, Potter CS, Sundberg JP, Hogenesch H. SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med. 2012;16:2271-2279.
6. Iwai K. Linear polyubiquitin chains: a new modifier involved in NFjB activation and chronic inflammation, including dermatitis. Cell Cycle. 2011;10:3095-3104.
7. Gerlach B, Cordier SM, Schmukle AC, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011;471:591-596.
8. Tokunaga F, Iwai K. LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses. Microbes Infect. 2012;14:563-572.
9. Sieber S, Lange N, Kollmorgen G, et al. Sharpin contributes to TNFa dependent NFjB activation and anti-apoptotic signalling in hepatocytes. PLoS One. 2012;7:e29993.
10. Tomonaga M, Hashimoto N, Tokunaga F, et al. Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol. 2012; 40:409-417.
11. Wang Z, Sokolovska A, Seymour R, Sundberg JP, Hogenesch H. SHARPIN is essential for cytokine production, NF-jB signaling, and induction of Th1 differentiation by dendritic cells. PLoS One. 2012;7:e31809.
12. Andela VB, Gordon AH, Zotalis G, et al. NFjB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. 2003;415(suppl):S75-S85.
13. Ban JO, Oh JH, Son SM, et al. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFjB via suppression of GSK-3b expression. Cancer Biol Ther. 2011;12:288-296.
14. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrinreleasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289-296.
15. Paduano F, Villa R, Pennati M, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther. 2006;5:179-186.
16. Shen HM, Tergaonkar V. NFjB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 2009;14: 348-363.
17. Sethi G, Sung B, Aggarwal BB. Nuclear factor-jB activation: from bench to bedside. Exp Biol Med (Maywood). 2008;233:21-31.
18. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-jB signaling in a mouse model of lung adenocarcinoma. Nature. 2009; 462:104-107.
19. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-jB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 1997;278:1812-1815.
20. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834-842.
21. Tergaonkar V. p53 and NFjB: fresh breath in the cross talk. Cell Res. 2009;19:1313-1315.
22. O'Prey J, Crighton D, Martin AG, Vousden KH, Fearnhead HO, Ryan KM. p53-mediated induction of Noxa and p53AIP1 requires NFjB. Cell Cycle. 2010;9:947-952.
23. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33:765-789.
24. Li W, Wang H, Kuang CY, et al. An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem. 2012;363:135-145.
25. Lin J, Guan Z, Wang C, et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NFjB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res. 2010;16:77-87.
26. Song K, Shankar E, Yang J, Bane KL, Wahdan-Alaswad R, Danielpour D. Critical role of a survivin/TGF-beta/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One. 2013;8:e61896.
27. Chung CY, Park YL, Kim N, et al. Expression and prognostic significance of livin in gastric cancer. Oncol Rep. 2013;30:2520-2528.
28. Xue D, Zuo K, Li X, et al. Expression and prognostic significance of livin, caspase-3, and Ki-67 in the progression of human ampullary carcinoma. Appl Immunohistochem Mol Morphol. 2013;21:525-531.
29. Myung DS, Park YL, Chung CY, et al. Expression of livin in colorectal cancer and its relationship to tumor cell behavior and prognosis. PLoS One. 2013;8:e73262.
30. Xu M, Xia LP, Fan LJ, Xue JL, Shao WW, Xu D. Livin and caspase-3 expression are negatively correlated in cervical squamous cell cancer. Eur J Gynaecol Oncol. 2013;34:152-155.
31. Li F, Yin X, Luo X, et al. Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling. Cell Signal. 2013;25:1413-1422.
32. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res. 2007;13:5995-6000.
33. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003; 253:89-101.
34. Nelius T, Filleur S, Yemelyanov A, et al. Androgen receptor targets NFjB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer. 2007;121:999-1008.
35. He L, Ingram A, Rybak AP, Tang D. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 2010;120:2094-2108.